Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schuchmann

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosisStefan Zeuzem, Vicente Soriano, Tarik Asselah, et al.
Antiviral Therapy|April 6, 2013
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final resultsStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology|January 7, 2015
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infectionPeter Ferenci, Tarik Asselah, Graham R Foster, et al.
Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.
Pageof 9